

April 30, 2021

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that Glenmark Pharmaceuticals Limited has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as Indo Health Services LLP).

The details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure – A.

Request you to kindly take the same on record.

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)

Annexure A

<p>a) Name of the target entity, details in brief such as size, turnover etc.:</p>	<p>i) Name of the Target entity: ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) (hereinafter referred to as Target entity).</p> <p>ii) Details of Target entity: The Target entity is a recently incorporated limited liability partnership (“LLP”) and is yet to commence business activities.</p>
<p>b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;</p>	<p>The transaction does not fall within the purview of related party transaction.</p> <p>None of the promoter/promoter group/group companies have any interest in the entity.</p>
<p>c) Industry to which the entity being acquired belongs;</p>	<p>Healthcare Services</p>
<p>d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);</p>	<p>Initiative with an objective to facilitate, enable and promote efficiency and Good Distribution Practices (“GDP”) including digitizing healthcare infrastructure in India, inter alia, in support of the National Digital Health Mission of Government of India (‘Business’).</p>
<p>e) Brief details of any governmental or regulatory approvals required for the acquisition;</p>	<p>None</p>
<p>f) Indicative time period for completion of the acquisition;</p>	<p>To be completed on or before 30th April 2021</p>
<p>g) Nature of consideration-whether cash consideration or share swap and details of the same;</p>	<p>Cash infusion as capital contribution</p>
<p>h) Cost of acquisition or the price at which the shares are acquired;</p>	<p>INR 40 crores</p>
<p>i) Percentage of shareholding / control acquired and/or number of shares acquired;</p>	<p>6.45% share of profit/ loss in LLP</p>
<p>j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);</p>	<p>The Target entity was incorporated on 10th February, 2021.</p> <p>The Target entity through its investments in DigiHealth Technologies LLP, Pharmarack Technologies Private Limited, Trikaal Mediinfotech Private Limited, and AIOCD Pharmasofttech Awacs Private Limited, aims to achieve the objectives as per clause (d) above.</p>

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com